We may be in the midst of one of the biggest biotech bull markets in history, but shares of controversial biotech company Amarin (NASDAQ:AMRN) have plunged more than 40% in the past 12 months. A number of issues have pressured shares, ranging from question marks over the market exclusivity of the company's fish-oil drug Vascepa to emerging generic competition. Despite this drop, Amarin has the opportunity to prove the naysayers wrong this month during an FDA advisory committee meeting that may recommend expanded approval for Vascepa.

The company announced last week that the government shutdown wouldn't change the date of this meeting, so investors should be prepared for this major catalyst. In the following video, analysts David Williamson and Max Macaluso discuss the significance of this meeting to Amarin's business and also examine competition from GlaxoSmithKline's (NYSE:GSK) Lovaza and AstraZeneca's (NYSE:AZN) experimental fish-oil pill, Epanova.


David Williamson owns shares of Amarin and Facebook. Max Macaluso, Ph.D. owns shares of Apple. The Motley Fool recommends and owns shares of Amazon.com, Apple, Facebook, and Google. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.